Skip to main content
. Author manuscript; available in PMC: 2017 Apr 19.
Published in final edited form as: Adv Funct Mater. 2016 Feb 1;26(15):2512–2522. doi: 10.1002/adfm.201504879

Figure 1.

Figure 1

(a) Induction of OVA-specific humoral and mucosal immune response 4 weeks after transdermal (t.d.) administration (blue), and laser-adjuvant (l.a.) transdermal administration (yellow) of OVA (mean ± SD, n = 4); n.s., P>0.05. (b) OVA-specific antibody titers measured at 4 weeks after intramuscular (i.m.) injection of OVA (500 μg) and 4 days after OVA challenge test (mean ± SD, n = 4); *, P < 0.05.